CPT code 80285: Voriconazole assay, drug concentration2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Measures voriconazole concentration in a laboratory specimen, commonly for therapeutic drug monitoring during antifungal treatment.
Medicare pays $27.11 for 80285 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$27.11
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 80285 covers
This assay measures voriconazole in a patient specimen to assess drug exposure during antifungal treatment. Clinicians may order therapeutic drug monitoring while treating serious fungal infections, because measured exposure can inform management of therapy. Clinical laboratories perform and report the assay; serum is commonly used for voriconazole concentration testing. Infectious disease and transplant clinicians may use the result when managing antifungal therapy.
Report 80285 for measurement of voriconazole itself; it identifies the drug assay, not a panel of antifungal levels. Medicare pays the test through the CLFS at one national amount across localities, with no office-versus-facility difference. The 2026 national CLFS amount is $27.11, unchanged since 2020. The test is paid only through the CLFS and is excluded from the physician fee schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 80285
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 80285. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 80285 with status X (excluded by statute), so the test itself is paid only from the CLFS.
80285 on the lab fee schedule since 2020
80285 · CLFS 2026 Q4 (current)
$27.11
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
80285 compared with similar tests
- 80299Drug assayUnlisted therapeutic drug$18.64
- 80285 specifically identifies a voriconazole assay. Use 80299 for a quantitative drug assay when no more specific assay code applies.
- 80202Vancomycin levelAntibiotic concentration$13.54
- 80202 identifies a vancomycin assay, not voriconazole. Choose the code for the drug actually measured.
- 80200Tobramycin levelAntibiotic monitoring$16.13
- 80200 identifies a tobramycin assay. It is not interchangeable with 80285, which measures voriconazole.
80285 billing questions
When should 80285 be selected instead of 80299?
Use 80285 when the assay measures voriconazole. Code 80299 is a general quantitative drug assay code for situations when a more specific assay code does not apply.
Does 80285 represent a panel of antifungal drug levels?
No. It identifies measurement of voriconazole; other drug assays are reported under codes for their respective analytes.
What specimen is commonly tested?
Serum is commonly used for voriconazole concentration testing.
When is voriconazole testing used?
Clinicians may order it for therapeutic drug monitoring during antifungal treatment, including treatment of serious fungal infections.
How does Medicare pay for 80285?
Medicare pays the test under the CLFS at one national amount across localities, with no office-versus-facility difference. It is excluded from the physician fee schedule.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 80285 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist